{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:52:57Z","timestamp":1785790377708,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.euo.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T05:20:41Z","timestamp":1713676841000},"page":"1005-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5013-7617","authenticated-orcid":false,"given":"Clara","family":"Cerrato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Crocerossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.03.014_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clgc.2019.10.020","article-title":"Sex differences in urothelial bladder cancer survival","volume":"18","author":"Radkiewicz","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2024.03.014_b0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.urolonc.2019.08.001","article-title":"Bladder cancer survival: women only fare worse in the first two years after diagnosis","volume":"37","author":"Richters","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrurol.2015.232","article-title":"Gender differences in incidence and outcomes of urothelial and kidney cancer","volume":"12","author":"Lucca","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13293-022-00428-0","article-title":"Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer","volume":"13","author":"Hamade","year":"2022","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.euo.2024.03.014_b0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","article-title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","volume":"619","author":"Abdel-Hafiz","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.euo.2024.03.014_b0030","unstructured":"Ljungberg B, Albiges L, Bedke J, et al. EAU guidelines on renal cell carcinoma. 2023. European Association of Urology Web site. https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma."},{"key":"10.1016\/j.euo.2024.03.014_b0035","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, et al. Guidelines on muscle-invasive and metastatic bladder cancer. 2023. European Association of Urology Web site. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer."},{"key":"10.1016\/j.euo.2024.03.014_b0040","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/jpm13091339","article-title":"Antibody\u2013drug conjugates for the treatment of renal cancer: a scoping review on current evidence and clinical perspectives","volume":"13","author":"Sganga","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.euo.2024.03.014_b0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cells11050803","article-title":"Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside","volume":"11","author":"Ungaro","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.euo.2024.03.014_b0050","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.juro.2011.12.099","article-title":"External validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinoma","volume":"187","author":"Wang","year":"2012","journal-title":"J Urol"},{"issue":"4_suppl","key":"10.1016\/j.euo.2024.03.014_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA359","article-title":"Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"42","author":"Choueiri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0060","series-title":"Cochrane handbook for systematic reviews of interventions version 6.3","author":"Higgins","year":"2022"},{"key":"10.1016\/j.euo.2024.03.014_b0065","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0070","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.euo.2024.03.014_b0085","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.03.014_b0090","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ijc.34608","article-title":"Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial","volume":"153","author":"Rha","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2024.03.014_b0095","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.03.014_b0100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.03.014_b0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.03.014_b0110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.03.014_b0115","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0120","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.03.014_b0130","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0140","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0150","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.03.014_b0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/biomedicines8070232","article-title":"Sex and gender influences on cancer immunotherapy response","volume":"8","author":"Irelli","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.euo.2024.03.014_b0160","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3389\/fimmu.2018.03167","article-title":"Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration","volume":"9","author":"Webb","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2024.03.014_b0165","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.euo.2020.08.013","article-title":"Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment","volume":"3","author":"Koti","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0170","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.isci.2022.104717","article-title":"Sex-biased adaptive immune regulation in cancer development and therapy","volume":"25","author":"Schafer","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.euo.2024.03.014_b0175","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00345-013-1037-z","article-title":"Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity","volume":"31","author":"Gakis","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41418-017-0051-x","article-title":"Sex disparity in cancer: Roles of microRNAs and related functional players","volume":"25","author":"Car\u00e8","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.euo.2024.03.014_b0185","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.3390\/cancers13184588","article-title":"Sex and gender differences in kidney cancer: clinical and experimental evidence","volume":"13","author":"Peired","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2024.03.014_b0190","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00345-023-04412-0","article-title":"Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis","volume":"41","author":"Yanagisawa","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0195","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00262-021-02882-y","article-title":"Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma","volume":"70","author":"Tulchiner","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2024.03.014_b0200","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1038\/srep09160","article-title":"Age-dependent association between sex and renal cell carcinoma mortality: a population-based analysis","volume":"5","author":"Qu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2024.03.014_b0205","article-title":"Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-\u03b2 activation","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2024.03.014_b0210","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.2147\/OTT.S172149","article-title":"Estrogen affects cell growth and IGF-1 receptor expression in renal cell carcinoma","volume":"11","author":"Sun","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.euo.2024.03.014_b0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/JU.0000000000000788","article-title":"Differential effect of sex on outcomes after radical surgery for upper tract and bladder urothelial carcinoma: a systematic review and meta-analysis","volume":"204","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0220","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00345-022-04116-x","article-title":"Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis","volume":"41","author":"Mori","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.03.014_b0225","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.3390\/ijms21165891","article-title":"Nectin4 expression in extramammary Paget\u2019s disease: implication of a new therapeutic target","volume":"21","author":"Murata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2024.03.014_b0230","article-title":"Prognostic value of nectin-4 in human cancers: a meta-analysis","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.euo.2024.03.014_b0240","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1007\/s00432-022-04309-2","article-title":"The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex","volume":"149","author":"Wahli","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2024.03.014_b0245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T23:36:11Z","timestamp":1727220971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2588931124000968"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.03.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}